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Abstract: Pseudoxanthoma elasticum (PXE), the prototype of heritable ectopic mineralization disorders, manifests with deposition of calcium hydroxyapatite crystals in the skin, eyes and arterial
blood vessels. This autosomal recessive disorder, due to mutations in ABCC6, is usually diagnosed
around the second decade of life. In the spectrum of heritable ectopic mineralization disorders are
also generalized arterial calcification of infancy (GACI), with extremely severe arterial calcification
diagnosed by prenatal ultrasound or perinatally, and arterial calcification due to CD73 deficiency
(ACDC) manifesting with arterial and juxta-articular mineralization in the elderly; the latter disorders
are caused by mutations in ENPP1 and NT5E, respectively. The unifying pathomechanistic feature
in these three conditions is reduced plasma levels of inorganic pyrophosphate (PPi), a powerful
endogenous inhibitor of ectopic mineralization. Several on-going attempts to develop treatments
for these conditions, either with the goal to normalize PPi plasma levels or by means of preventing
calcium hydroxyapatite deposition independent of PPi, are in advanced preclinical levels or in
early clinical trials. This overview summarizes the prospects of treatment development for ectopic
mineralization disorders, with PXE, GACI and ACDC as the target diseases, from the 2020 vantage
point.
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1. Introduction
1.1. Clinical Features of Pseudoxanthoma Elasticum
Pseudoxanthoma elasticum (PXE) is the prototype of heritable multisystem ectopic
mineralization disorders with protean manifestations. PXE is in most cases initially diagnosed with characteristic skin findings, consisting of yellowish papules on the flexural
predilection sites, including the sides of the neck, and axillary and inguinal areas. These
lesions tend to coalesce into large plaques of inelastic, leathery skin with sagging and loss
of recoil [1,2] (Figure 1; Table 1). Histopathology of the skin demonstrates accumulation of
the pleomorphic elastotic material in the mid dermis as demonstrated by elastin specific
stains (Verhoeff-van Gieson or Orcein). This aberrant elastotic material becomes calcified
as demonstrated by transmission electron microscopy or by histopathologic staining with
calcium phosphate stains (von Kossa or Alizarin red). While the skin manifestations can be
extensive, expanding to cover most of the body, the cutaneous findings are primarily of
cosmetic concern.
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cardinal symptom. Clinical manifestations of vascular involvement, although less frequent,
also include hypertension and occasional bleeding of the gastrointestinal vessels. In some
families, there can be severe vascular involvement, including development of arterial
aneurysms and occasional early myocardial infarcts and strokes.
Table 1. Clinical and genetic features of PXE, GACI, and ACDC.
Characteristics
Genetic basis
Mutated genes
Clinical features
Yellowish skin papules
Mineralization in skin lesions
Retinal angioid streaks
Vascular calcification
Periarticular calcification
Hearing loss
Hypophosphatemic rickets
Age at onset
Life expectancy
Plasma PPi levels

PXE

GACI

ACDC

ABCC6, ENPP1

ENPP1, ABCC6

NT5E

Yes
Yes
Yes
Yes
No
No
No
Adolescence, early
adulthood

Rare
Yes
Rare
Yes
Yes
Yes
Yes (survivors)
Pre- and perinatal
onset
Demise common <6
months
Reduced to 0

No
No
No
Yes (lower extremity)
Yes
No
No

Mostly normal
Reduced to ~40%

Adult onset
Normal
Reduced to ~50%

PXE, pseudoxanthoma elasticum; GACI, generalized arterial calcification of infancy; ACDC, arterial calcification
due to deficiency of CD73.

1.2. Genetics and Pathophysiology of PXE
PXE is an autosomal recessive disorder with complete penetrance. Earlier suggestions
of autosomal dominant inheritance in some families have been discounted by more recent
genetic analyses, and occasional demonstrations of inheritance in two subsequent generations have been shown to reflect pseudodominance in consanguineous families [7]. The
majority of PXE patients harbor biallelic mutations in the ABCC6 gene, which encodes an efflux transporter protein ABC-binding cassette subfamily C, member 6 (ABCC6), expressed
primarily in the liver and to a lesser extent in the proximal tubules in the kidneys [8,9].
ABCC6 is not expressed in tissues demonstrating ectopic mineralization or in the principal
cells of such tissues, as for example dermal fibroblasts. Under physiological conditions,
ABCC6 facilitates transport of adenosine triphosphate (ATP) from the hepatocytes to the
extracellular milieu where ATP is readily converted to adenosine monophosphate (AMP)
and inorganic pyrophosphate (PPi) [10,11]. The latter is a powerful physiological antimineralization factor which interferes with hydroxyapatite crystal growth by binding
to the initial nucleus of mineralization and preventing calcium phosphate deposition. In
patients with PXE with nonfunctional ABCC6, the plasma levels of PPi are reduced to
about 40% of the level in normal healthy individuals, which is reproducibly in the range
of 1 µM measured by using a number of analytical techniques [12,13]. Reduced PPi levels
then allow the growth of calcium hydroxyapatite crystal deposits on the surfaces of the
extracellular matrix, particularly the elastic structures. It should be noted that in PXE
patients, ectopic mineralization takes place in essentially all tissues with elastic structures,
yet clinical manifestations are limited to the skin, eyes, and the arterial blood vessels [14].
The PPi concentration in plasma is regulated by a number of factors. First, as indicated,
the majority of PPi is derived from enzymatic hydrolysis of ATP by ENPP1, an ectonucleotide pyrophosphatase/phosphodiesterase generating AMP and PPi. However, since in
complete absence of functional ABCC6, as in most cases with PXE, there is a residual of 40%
of PPi in plasma, apparently reflecting other sources of ATP which can serve as a substrate
for ENPP1 in extrahepatic tissues. At the same time, circulating PPi has a relatively short
half-life, estimated to be approximately 42 min [15,16], due to its enzymatic hydrolysis to
inorganic phosphate (Pi) by tissue nonspecific alkaline phosphatase (TNAP). The activity
of this enzyme is physiologically inhibited by adenosine which is derived from further
hydrolysis of AMP by another ectonucleotidase CD73 encoded by the NT5E gene [17].
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Since in the absence of functional ABCC6, AMP levels as a substrate are also reduced, there
is a reduction of adenosine plasma levels leading to reduced inhibition of TNAP activity,
thus collectively leading to reduced PPi plasma levels in PXE by different mechanisms.
1.3. Related Ectopic Mineralization Disorders
While PXE is characteristically of late onset and a slowly progressive disorder, a
few cases with characteristic features of PXE have been described in early infancy, diagnosed as pediatric PXE. However, another disease, generalized arterial calcification of
infancy (GACI) is a severe ectopic mineralization disorder with primarily vascular calcification, manifesting very early on, often diagnosed by routine prenatal ultrasound at the
14th-15th weeks gestation (Figure 1; Table 1). These patients are born with extensive vascular mineralization, neointimal hyperplasia and cardiovascular insufficiency, and without
treatment, these children frequently die within the first year of life from cardiovascular
complications [18]. Characteristic cases of GACI, designated as GACI-1, with early onset
ectopic mineralization, harbor biallelic loss-of-function mutations in the ENPP1 gene, and
their circulating PPi levels, as deduced from the corresponding Enpp1−/− mouse models [19], are essentially zero, allowing early aberrant mineralization to take place with
serious phenotypic consequences [20,21]. Interestingly, some of the GACI patients, designated as GACI-2, have been shown to harbor mutations in the ABCC6 gene, instead
of ENPP1, demonstrating a genotypic and early phenotypic overlap between GACI and
PXE [22,23].
A third example of ectopic mineralization is arterial calcification due to CD73 deficiency (ACDC), a late-onset Mendelian disorder affecting arterial blood vessels by ectopic
mineralization in the lower extremities and in periarticular tissues [17] (Figure 1; Table 1).
ACDC is a very rare condition, and only a few families have been carefully examined for
genetics and underlying mutations. The genetic basis of this condition resides in the NT5E
gene, and in the absence of the CD73 activity, the adenosine levels are reduced resulting
in activation of TNAP and again contributing to the reduced PPi plasma levels [3,24].
Thus, the unifying pathomechanistic feature in these three heritable ectopic mineralization disorders, viz., PXE, GACI, and ACDC, revolves around reduced PPi concentrations
in the plasma, and the overall levels of this molecule, in general terms, translate to the
severity and the average age of onset of the disease. It should be noted that a number
of contributing factors, besides the primary genetic defects, can modulate the phenotype
in different families with distinct mutations and even between affected members within
the same family, clinically recognized as considerable intra- and interfamilial phenotypic
heterogeneity. Such contributing factors have been postulated to include modifier genes,
epigenetic factors, and environmental and lifestyle variables, such as exercise and diet [25].
Nevertheless, there is no effective treatment currently available for systemic mineralization
in these three conditions, but several recent preclinical developments and early clinical
trials hold promise for potential treatments in the near future (Table 2). Among these
efforts, PXE is the most studied disease for therapeutics development (Figure 2).

J. Clin. Med. 2021, 10, 114

5 of 16

Table 2. Interventional preclinical studies and early clinical trials for PXE, GACI, and ACDC, published and on-going.
Treatment
Preclinical trials
Sevelamer hydrochloride
Magnesium
Statin
Chaperone therapy
PTC-read through drug
Bisphosphonates

Rationale/Target
Phosphate binder
Competes with calcium to prevent calcium
hydroxyapatite crystal formation
Lipid-lowering drug
Corrects the trafficking defect of misfolded
ABCC6 protein
Read-through of PTC codons
Stable nonhydrolyzable PPi analogs

Diagnosis

Publications

PXE

[26]

PXE

[27–29]

GACI
PXE

[30]
[31]

PXE

[15,32–34]

PXE
PXE
GACI

[35]
[15,36,37]
[38,39]

PXE

[15,16,40]

PPi administration

Correction of reduced plasma PPi levels in PXE
and GACI

GACI

[16]

ENPP1 protein replacement

ENPP1 is the principal enzyme that generates
PPi

PXE

[41]

TNAP inhibitor

TNAP is the enzyme that breaks down PPi

GACI
PXE
GACI

[42,43]
[44,45]
[44]

Gene therapy

ABCC6 gene therapy to reconstitute hepatic
ABCC6

PXE

[46]

PXE

[47]

PXE

[48]

PXE
PXE
PXE
GACI
ACDC

[49]
[50]
[51,52]
[18,53,54]
NCT01585402 *

PXE

[55]

PXE

[56]

PXE

NCT04441671 *

Clinical trials
Aluminum hydroxide 1)
VEGF antagonists 2)
Sevelamer hydrochloride 3)
Magnesium 4)
Bisphosphonates 5)

VEGF antagonist 6)
Sodium thiosulfate 7)
PPi administration

Phosphate binder
Bevacizumab and ranibizumab, inhibitors of
vascular endothelial growth factor for the
treatment of choroidal neovascularization
Phosphate binder
Prevention of ectopic mineralization
Stable nonhydrolyzable PPi analogs

Aflibercept, an inhibitor of vascular endothelial
growth factor for the treatment of choroidal
neovascularization
Antioxidant properties and chelation of calcium
to form soluble calcium thiosulfate complexes
Correction of reduced plasma PPi levels in PXE
and GACI

PXE, pseudoxanthoma elasticum; GACI, generalized arterial calcification of infancy; ACDC, arterial calcification due to deficiency of
CD73. * ClinicalTrials.gov Identifier; 1) Six PXE patients, 1-year follow-up. Three patients showed significant clinical improvement and
histopathologic regression of calcification in the skin lesions. No deterioration of eye disease was observed in any of the six patients;
2) Long-term results of intravitreal antivascular endothelial growth factors, bevacizumab and ranibizumab, in the management of choroidal
neovascularization in nine PXE patients with angioid streaks. During the mean follow-up period of 28.6 months, visual acuity was either
improved or stabilized in all patients without complications; 3) Randomized, double-blind, placebo-controlled, prospective clinical study
in 40 patients with PXE. While reduction in both calcification levels and clinical scores of the skin were noted, the differences were not
statistically significant compared with placebo; 4) The NCT01525875 magnesium trial was a randomized, double-blind, placebo-controlled
prospective trial that evaluated the effect of oral magnesium oxide (MgO) versus placebo on the skin and eyes in 44 PXE patients. Although
not statistically significant, the treatment group was found to have decreased elastic fiber calcification in the skin. No significant treatment
effect was observed in the ophthalmologic outcomes; 5) The Treatment of Ectopic Mineralization in Pseudoxanthoma Elasticum trial
(NTR5180) tested the effects of etidronate in 74 PXE patients with leg arterial calcifications (mean age: 57 years, range 48–66) randomly
assigned to etidronate or placebo. During 12 months of follow-up, etidronate reduced arterial calcification and subretinal neovascularization
events without important safety issues; 6) The NCT02537054 trial was a 12-month prospective, open-label, uncontrolled, nonrandomized
interventional clinical trial testing the effects of 2 mg intravitreal aflibercept for treatment of choroidal neovascularization (CNV) secondary
to angioid streaks, in 15 PXE patients (mean age: 53 years, range 22–65). After 12 months of treatment, aflibercept improved or stabilized
best corrected visual acuity (BCVA), central retinal thickness (CRT), retinal sensitivity, and vision-related quality of life in the majority of
patients; 7) Intravenous sodium thiosulfate was administered in a young patient with PXE-like syndrome. This 11-year old patient, with
severe early-onset systemic calcifications occurring in the skin and in the arteries, demonstrated radical improvement in asthaenia, anorexia
and pre-/postprandial pain and calcific stenosis after six months of treatment.
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Table 2. Interventional preclinical studies and early clinical trials for PXE, GACI, and ACDC, published and on-going.

1.4. Development of Animal Models
Treatment
Rationale/Target
Diagnosis
Publications
Much of the recent
progress in development of therapeutic
modalities
for ectopic
Preclinical trials
mineralization disorders, primarily focusing on PXE, has been based on preclinical testing
Sevelamer hydrochloride in animal
Phosphate
binder
PXE
[26] gene in patients
models.
Following the demonstration of mutations
in the ABCC6
Magnesium
with models
calciumconsisting
to prevent of
calcium
withCompetes
PXE, animal
Abcc6 hydroxygene knockout (Abcc6−/− ) in mice were
PXE
[27–29]
developed
[57,58].formation
These animals recapitulate the features of human PXE by relatively
apatite crystal
late onset of mineralization in the skin, eyes, and the arterial
blood vessels.
GACI
[30] Subsequently,
a number
of inbreddrug
mouse strains with a spontaneous mutation
in the
Abcc6 gene were
Statin
Lipid-lowering
PXE
[31]
identified,
allowing
investigation
of
phenotypic
variability
in
mice
with
the same Abcc6
Chaperone therapy
Corrects the trafficking defect of misfolded ABCC6
PXE
[15,32–34]
allelic
mutation
on
different
genetic
strain
backgrounds
[59,60].
In
addition
to mouse
protein
models, a rat model for PXE has also been developed by inactivation of Abcc6 by zinc finger
PTC-read through drug
Read-through of PTC codons
PXE
[35]
nuclease technology; this larger rodent model allows more detailed pathophysiological
Bisphosphonates
Stable nonhydrolyzable PPi analogs
PXE
[15,36,37]
studies, such as liver and kidney perfusions, to be conducted [61]. These rodent models
GACI
[38,39]
have served as a platform for a number of preclinical studies, some of which have led to
PPi administration
Correction
of reduced
plasma PPi levels in PXE and
early
clinical trials
(Table 2).
PXE
[15,16,40]
GACI
A number of animal models are also available to study GACI caused by ENPP1 mutaGACI calcification
[16]
tions. The genetically engineered Enpp1−/− mice display vascular
phenotypes
asj
asj
−
2J
ENPP1 protein replacement
ENPP1
is the principal
enzyme
that generates
PPi
PXE
similar
to human
GACI [62].
The Enpp1
and Enpp1
mice, both[41]
developed at The
GACI of stiffening
[42,43] of the joints,
Jackson Laboratory, Bar Harbor, ME, display phenotypic features
hence
“ages
stiffened
joints”
(asj).
These
a missense [44,45]
mutation, p.V246D,
TNAP inhibitor
TNAP
is with
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that
breaks
down
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[63,64].
The
GACI
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(Enpp1
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Gene therapy
ABCC6
gene therapy
to reconstitute
hepatic
ABCC6
PXEcodon mutation
[46]
the
Enpp1
gene,
exhibits
ectopic
mineralization
phenotype
similar
to
those
in
Enpp1−/−
Clinical trials
[65].
Aluminum hydroxide 1) micePhosphate
binder
PXE
[47]
A
mouse model developed in 2004 to study tubuloglomerular feedback-dependent
VEGF antagonists 2)
Bevacizumab and ranibizumab, inhibitors of vascuresponses, was recently recognized to have features of ACDC. This mouse, developed by
lar endothelial growth factor for the treatment of
PXE
[48]
ablation of the Nt5e gene, showed profound mineralization of the costochondral junctions,
choroidal neovascularization
juxta-articular joint capsules as well as ligaments adjacent to the bony structures, features in
3)
Sevelamer hydrochloride patients
Phosphate
binder[24,66]. These mice, however, do not PXE
[49] mineralization
with ACDC
develop vascular
4)
Magnesium
Prevention of ectopic
mineralization
PXE
[50]
as characteristically
seen in
human disease.
Bisphosphonates 5)
Stable nonhydrolyzable PPi analogs
PXE
[51,52]
GACI
[18,53,54]
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2. Therapy Development for Ectopic Mineralization Disorders
2.1. Dietary Magnesium
Early literature suggested that excessive dietary intake of dairy products in the early
childhood and adolescence may result in more severe presentation of PXE later in life, and
this was taken as an indication of the role of dietary calcium in ectopic mineralization, with
a corresponding advice for the PXE patients to limit their calcium intake [1]. To provide
scientific basis for this recommendation, one of the early studies on PXE mouse models
tested the effects of a number of dietary minerals on the severity of the disease. These
studies demonstrated that dietary calcium did not have any effect on ectopic mineralization
in the mouse model of PXE. However, it was noted that increased magnesium content of
the diet fed to the mice had a profound effect on the degree of mineralization. Specifically, increase of the magnesium content by 5-fold over the regular diet completely abolished the ectopic mineralization in the PXE mice [27–29]. Elevated dietary magnesium by
5-fold during pregnancy and postnatal life also prevented the ectopic mineralization in
the Enpp1asj mice [30]. Conversely, reduction of the magnesium content to 20% of the
control diet resulted in significant acceleration of the mineralization process [67]. The mechanism by which elevated dietary magnesium prevents ectopic mineralization involves
competition of magnesium for calcium in complexing with inorganic phosphate. Since
magnesium phosphate complexes are more soluble than calcium phosphate particles, less
hydroxyapatite precipitation and crystal formation occurs.
Based on these preclinical observations, a two-year clinical trial supplementing PXE
patients’ diet with magnesium was initiated. The recommendation of the United States
Food and Drug Administration for daily magnesium content of diet is 420 mg for adult
male and 320 mg for adult female. The first year of this placebo-controlled trial consisted
of placebo or supplementation of diet with magnesium oxide (MgO), 800 mg twice a day (a
total of 1000 mg of elemental magnesium), with 22 individuals enrolled in each group [50].
The effect of the treatment was monitored by examination of the extent of skin lesions
and obtaining skin biopsies for assessment of the degree of calcification at the beginning
and the end of one year treatment period, the primary endpoint being calcification of skin
elastic fibers. At the end of a double-blinded one year period, all 44 individuals were
encouraged to continue on supplementary magnesium intake, 2500 mg of MgO (1500 mg
of elemental magnesium).
During the double-blinded, placebo-controlled phase, the magnesium group had a
decrease, yet not reaching statistical significance, in calcification of the skin elastic fibers,
whereas the placebo group did not demonstrate any changes. Setting a 30% decrease in
elastic fiber calcification as a secondary endpoint, 36% of patients in the treatment group
were responders compared with only 14% of patients in the placebo group. The authors
concluded that, although not statistically significant, this trend might be clinically significant [50]. A similar trend was noted in assessment of the cutaneous lesions, but no
significant treatment effect was observed in the ophthalmological outcomes. The investigators pointed out that this study had limitations that likely contributed to the lack of
statistical significance, including the relatively small cohort size. In addition, the dose of
magnesium was limited because of concern of gastrointestinal side effects, particularly diarrhea. Despite these limitations, the results highlight a promising trend showing reduction in
calcification of skin elastic fibers while on magnesium supplementation. A larger study cohort could further elicit the value of magnesium supplementation as an antimineralization
therapeutic either as a monotherapy or in combination with other approaches.
2.2. Phosphate Binders
One of the observations in the initial preclinical studies using Abcc6 knockout mice as
a platform to study the modulation of the PXE phenotype was that dietary phosphate had
a profound effect on the degree of mineralization. Specifically, increasing the phosphate
content of the diet by 2-fold clearly accelerated the mineralization in this mouse model,
particularly when coupled with magnesium content reduced to 20% of the control diet [67].
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This so-called “acceleration diet” (2-fold increase in Pi, 20% Mg2+ , and 22-fold increase in
vitamin D content) has been used to accelerate the mineralization in rodent models of PXE,
thus speeding up the preclinical trials towards development of treatment modalities.
Considering that phosphate promotes the mineralization process, limited early clinical
trials have been performed with phosphate binders as pharmacological agents limiting
the intestinal absorption of phosphate in patients with PXE. In the first early study, six
patients were treated with aluminum hydroxide and evaluated by skin photography and
lesion assessment [47]. Repeated skin biopsies were also performed on clinically improved
target sites, and ophthalmologic evaluation was performed at yearly intervals. Of the six
patients, three showed apparent clinical improvement of skin lesions with histopathologic
regression of the disease. No deterioration of eye involvement was noted.
This relatively small study was expanded to include 40 patients with PXE randomized
to receive either sevelamer hydrochloride (800 mg by mouth 3 times daily) or placebo up
to one year [49]. During the second year, all patients received sevelamer hydrochloride.
A decrease in the calcium score was noted during the first year both in the treatment and
placebo group, and in the second year the calcium scores decreased further. The mean
clinical scores also improved in the sevelamer treated patients more significantly than
in the placebo group. The authors concluded that sevelamer hydrochloride can produce
a reduction in both calcification levels and clinical scores, but this difference was not
statistically significant compared with placebo. The improvement in placebo group could
possibly reflect the fact that both the placebo and the active drug preparations contained
magnesium stearate as an inactive ingredient, which may have played a confounding role
in this study.
2.3. Atorvastatin
ABCC6 has been suggested as a new player in cellular cholesterol and lipoprotein
metabolism, as described for other ABC transporters [68]. Early studies suggested that
cholesterol-lowering drugs, such as atorvastatin, was able to ameliorate the extent of
ectopic mineralization in the Abcc6−/− mouse model [31]. In contrast, an atherogenic diet
induced hypercholesterolemia and steatosis accompanied by increased mineralization in
the soft connective tissues in the same mouse model [69]. These findings have clinical
relevance for the management of PXE in humans.
2.4. Inorganic Pyrophosphate
Following the demonstration of the critical role of reduced PPi plasma levels in
the pathomechanism of PXE, a logical thought was to augment the PPi levels by oral
administration. This notion was initially discarded because the earlier literature had
suggested that PPi does not get absorbed from the intestine [70]. In fact, PPi, which is
commonly used by the food industry as an emulsifier, was considered to be completely
inactive when administered by mouth. However, subsequent studies in mice and human
volunteers clearly documented that a small fraction, in the order of 0.3% of the total dose
of tetrasodium-PPi administered orally, is absorbed and is able to elevate the plasma PPi
levels [16,70]. Subsequent studies demonstrated that oral administration of tetrasodiumPPi inhibited connective tissue mineralization in both Abcc6−/− and Enpp1asj mice [16].
Further modifications, including use of a disodium-PPi, was tested in individuals with
PXE, without apparent gastrointestinal side effects, potentially providing a new treatment
modality for PXE and related ectopic mineralization disorders [71]. Based on these studies,
a disodium-PPi absorption trial in PXE patients is under way (NCT04441671; last updated
22 June 2020).
2.5. Bisphosphonates
Bisphosphonates are stable analogs of PPi in which the oxygen linkage between phosphonate (PO3) groups has been replaced by a carbon molecule, thus providing stability
to the molecule against hydrolysis by TNAP [72]. In addition, bisphosphonates have two
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side groups (R1, R2) which can be chemically modified, providing unique pharmacokinetic
characteristics, pharmacologic profiles, and potency. Bisphosphonates have been developed as drugs to counteract osteoporosis, but in principle, they have two different effects:
(a) they can serve as an antimineralization compound, and (b) they promote bone calcification by being powerful antiosteoclastic molecules. The initially synthesized bisphosphonates, such as etidronate, have a higher relative antimineralization activity as compared
to the antiosteoclastic activity. However, the more recently synthesized, N-containing
bisphosphonates, such as alendronate, which are multiple orders of magnitude more powerful than etidronate, favor the antiosteoclastic activity. Based on these considerations,
etidronate, as a stable PPi analog, was initially tested in the mouse models for PXE for its
efficacy as an antimineralization factor. The results clearly demonstrated that etidronate,
although at relatively high concentrations, were able to prevent ectopic mineralization in
the mouse model of PXE [36]. Similar observations were also made in GACI mice with
deficient ENPP1 activity. In the latter mice, which also demonstrate extensive bone abnormalities, correction of the defective bone mineralization was noted as a result of etidronate
treatment [38,39]. Interestingly, administration of alendronate to these mouse models did
not demonstrate significant antimineralization activity, consistent with its characteristics
primarily as an antiosteoclastic compound.
Based on the preclinical studies on bisphosphonates, a clinical trial treating PXE
patients with etidronate was initiated, and this double-blinded trial included 74 patients,
evenly divided into the etidronate and placebo groups (Clinical Trial Code NTR5180) [51].
The patients were cyclically administered placebo or etidronate, 20 mg per kg/per day for
2 weeks every 12 weeks. The primary outcome was ectopic mineralization of the femoral
arterial wall as quantified by 18 fluoride positron emission tomography (18 F-NaF-PET) and
computed tomography (CT) scans. Although there was considerable variability between
individuals, the investigators demonstrated that during the initial 12-month treatment
period, arterial calcification in the lower extremities decreased 4% in the etidronate group
and increased 8% in the placebo group. Etidronate treatment was also associated with
significantly fewer subretinal neovascularization events, leading to the conclusion that
etidronate may be helpful for treatment of patients with PXE. Thus, the results suggested
that etidronate can halt the progression of femoral artery calcification, and possibly facilitate
removal of some of the existing hydroxyapatite lesions [51,73].
As a follow-up of the initial report, the investigators have published a comprehensive
survey of all vasculature with respect to ectopic mineralization in these patients and
the effect of etidronate treatment [52]. As a prespecified post-hoc analysis of the initial
study, calcification mass was quantitated in a number of arterial blood vessels, including
thoracic and abdominal aorta, using CT as a baseline and after one year of treatment with
etidronate or placebo. The results revealed that etidronate significantly halted progression
of calcification in all vascular beds examined, except for the coronary arteries. These results,
therefore, revealed that etidronate treatment can halt systemic arterial calcification in PXE,
emphasizing its potential usefulness for treatment of this disorder. However, as the authors
noted, further research must assess the long-term safety and efficacy of etidronate on
clinical outcomes.
The efficacy of bisphosphonates for treatment of GACI has also been tested in limited
number of patients, with encouraging results. Specifically, a retrospective observational
analysis of 55 patients with GACI revealed survival beyond infancy with etidronate therapy [18], which was corroborated by another study reporting that 15 of 22 GACI patients
who received etidronate treatment survived beyond infancy [74]. Bisphosphonates have
also been reported to be accompanied by severe side effects, particularly on the development of bones [75].
In addition to PXE and GACI, an etidronate trial is currently underway to investigate
whether etidronate is a safe and effective treatment for ACDC (NCT01585402; last update
10 July 2020), which is also accompanied by reduced plasma PPi levels.
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2.6. Tissue Nonspecific Alkaline Phosphatase (TNAP) Inhibitors
One approach towards increasing plasma PPi levels involves inhibition of TNAP,
the principal enzyme that facilitates degradation of PPi. The effects of TNAP inhibition,
genetically and pharmacologically, have been tested in both Abcc6−/− and Enpp1asj mice. In
a genetic model, the compound Alpl+/− ;Abcc6−/− mice, with approximately 50% reduced
TNAP levels, had dramatic reduction of ectopic mineralization as compared to age-matched
Alpl+/+ ;Abcc6−/− mice, despite unchanged plasma PPi levels [44]. In addition, administration of SBI-425, a small molecule inhibitor of TNAP, prevented ectopic mineralization in
the Abcc6−/− mice [44,45]. Several small molecules modified from SBI-425 with several
folds higher potency and better pharmacological properties are currently being developed.
2.7. ENNP1 Enzyme Replacement Therapy
With the focus on efforts to normalize the plasma PPi levels in patients with ectopic
mineralization disorders, some recent studies have concentrated on ENPP1, the key enzyme
catalyzing the hydrolysis of ATP to AMP and PPi. In patients with mutations in the ENPP1
gene, this enzymatic activity can be very low or essentially absent, and replacement therapy
with recombinant enzyme is expected to result in normalization of the PPi plasma levels
with stabilization of the disease. Initial studies using Enpp1asj mice, in fact, revealed that
administration of recombinant ENPP1 protein counteracted the phenotype, and specifically,
the treatment prevented mortality, vascular calcification, and improved blood pressure
and cardiovascular function [42]. Thus, ENPP1 replacement therapy would be expected to
correct or counteract the development of the GACI phenotype in humans as well.
ENPP1 replacement therapy has also been suggested for PXE. While the primary genetic defect in this disorder resides in the ABCC6 gene, cellular studies have suggested that
the activity of ENPP1, which resides downstream of ABCC6 in the pathway in generation
of PPi, is also reduced, and ENPP1 supplementation could augment PPi production from
ATP in extrahepatic tissues independent of ABCC6. Genetic overexpression of human
ENPP1 normalized plasma PPi levels and significantly prevented ectopic mineralization in
the Abcc6−/− mice, suggesting that the ENPP1 replacement therapy is also applicable to
patients with PXE [41].
2.8. Prospects of Allele-Specific Therapies
A number of potential treatment approaches for PXE have also been examined at
either utilizing PXE mouse models or cells with ABCC6 mutations at early preclinical level,
but these studies have not yet led to clinical trials. Some of these approaches are allelespecific, i.e., applicable only to a subset of patients with specific types of mutations. These
approaches include read-through of premature termination codon (PTC) in the ABCC6
gene with the prototypic nonsense codon read-though-inducing drug, PTC124. Utilizing
human HEK293 cells transfected with human ABCC6 expression constructs harboring
different PXE-associated nonsense mutations, these studies demonstrated that PTC124 was
able to facilitate PTC read-through, but the efficacy varied not only with dose but also
with the sequence context of the stop codon [35]. Thus, these results suggested that readthrough of nonsense mutations in ABCC6 by PTC124 may have potential for pharmacologic
treatment of some patients with PXE, and development of this, and other allele-specific
drugs, emphasize the importance of knowledge of the precise sequence information of the
mutant alleles.
Another allele-specific treatment modality, limited to a subgroup of patients with
distinct ABCC6 missense mutations, deals with molecular chaperones for correcting the
intracellular trafficking defect of the mutant protein. Specifically, molecular studies have
identified PXE mutations resulting in synthesis of catalytically active ABCC6 protein, but
its intracellular transport to the basolateral surface of hepatocytes is perturbed, leading to
cytoplasmic accumulation. In case of some of these mutations, the intracellular trafficking
defect can be corrected by treatment of cells with a chaperone molecule, 4-phenylbutyrate,
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which is already in clinical use for urea cycle disorders and thalassemia, thus possibly
offering a treatment modality for selected patients with PXE [15,32–34].
2.9. Prospects of Gene Therapy
A considerable amount of investigation has been devoted for development of gene
therapy for metabolic disorders with the primary defect in the liver, and some of these
are already in clinical trials, as exemplified by hemophilia [76]. Preliminary attempts have
been made to develop gene therapy for PXE, with the goal to introduce a functional copy
of the ABCC6 gene into the Abcc6−/− mice. For this purpose, an adenovirus construct into
which a full-length ABCC6 cDNA had been incorporated was injected into the tail vein of
these mice in a manner that the vector reaches liver [46]. The results demonstrated strong
hepatic expression of the transgenic human ABCC6, and this expression was sustained
up to 4 weeks after a single injection. However, since this model employed adenovirus
which has a high immunogenic potential, an immunologic suppression of the mouse was
required, a situation complicating the development of this vector for human application.
Viral vectors with less immunogenicity, such as adeno-associated virus, can be tested in
human trials.
2.10. VEGF Antagonists
To prevent visual impairment caused by choroidal neovascularization in patients
with PXE, intravitreal injections of anti-VEGF compounds are now in routine use with
considerable success [77,78]. The pharmaceutical agents, bevacizumab and ranibizumab,
antagonists of VEGF, which were initially tested, hold promise for long-term control of
choroid neovascularization in PXE, and intravitreal injections of other VEGF antagonists,
for example aflibercept, have been recently presented to be effective in prevention of loss of
visual acuity [55]. It should be noted that the VEGF antagonists target only neovascularization, a consequence of calcification of the Bruch’s membrane, and they do not antagonize
the mineralization process per se.
2.11. Potential Treatments for Reversal of the Existing Calcium Hydroxyapatite Crystals
One of the considerations regarding the treatment approaches currently under development, as summarized above (Table 2), relates to the fact that they are primarily
preventing further mineralization by arresting the hydroxyapatite crystal growth, and
it is unclear whether they are able to reverse the existing mineralization as a result of
endogenous turnover of the tissues with mineral deposits. This is an obvious concern to
the individuals affected by these conditions, because already at the time of diagnosis, they
have significant calcium deposits which explain their clinical features leading to correct
diagnosis. The future efforts should, therefore, also focus on pharmacological approaches
which would dissolve the existing mineral deposits. Such possibilities include systemic
administration of pharmacologic agents which would elicit dissolution of calcium phosphate complexes, such as calcium chelator citrate, now in clinical use for prevention of
calcium-containing kidney stones [79]. In this context, kidney stones, a major public health
challenge, have also been reported as a frequent manifestation in patients with PXE. In one
study, a 39.8% prevalence of kidney stones in 113 French PXE patients was reported [80].
Furthermore, in a recent study on a cohort of 563 PXE patients residing in the United States,
23% of them reported to have a history of kidney stones, a significant increase compared to
9.2% in the US general population [81]. A number of novel therapeutic agents to counteract
ectopic mineralization are currently in preclinical or early clinical testing. Such molecules
include inositol hexaphosphate (INS-3001) and myo-inositol hexaphosphate (SNF472),
potential inhibitors of ectopic mineralization [82,83] but whether they will elicit reversal
of the existing mineral deposits is currently unknown. In addition, although transient,
the efficacy of intravenous sodium thiosulfate in dissolution of ectopic calcification was
demonstrated in one PXE patient with severe early-onset manifestations [56]. Finally, in
addition to systemic therapies, development of targeting strategies to limit the delivery of
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the dissolving agents to arterial elastic fiber associated mineral deposits has been reported
using conjugates of antielastin antibody nanoparticles coupled with EDTA, a powerful
calcium solubilizing chemical [84]. Further work is necessary to investigate the preclinical
and clinical potential of these approaches for removal of existing mineralization in PXE,
GACI, and ACDC.
3. Conclusions and Future Perspectives
Our understanding of the genetic basis and molecular details of the pathomechanisms
of heritable ectopic mineralization disorders has tremendously expanded over the past
decade, and this knowledge has now identified a number of potential targets for treatment
development [2]. Specifically, the common pathomechanistic feature with heritable ectopic
mineralization disorders discussed in this review, PXE, GACI, and ACDC, revolves around
the role of reduced PPi plasma levels, with the notion that normalization of PPi could
prevent further ectopic mineralization, potentially stabilizing the disease. Such normalization could potentially include oral administration of PPi or its derivatives with different
pharmacokinetics which might lead to sustained elevation of PPi. TNAP inhibitors, which
would prevent degradation of PPi, could also lead to elevated PPi plasma levels. One of the
stable PPi analogs, etidronate, is already in clinical trials and has been shown to prevent
the ectopic mineralization of arterial blood vessels in PXE [51,52]. In addition, etidronate
has been tested in a few selected cases of GACI to examine whether administration of
etidronate to pregnant mothers and to the affected infants postpartum would be reducing
the cardiovascular complications [18,53]. If successful, some of these treatments focusing on PPi levels could be complemented with treatment modalities counteracting other
mechanisms of mineralization, including magnesium or phosphate binder administration,
which in combination could prevent the progression of the disease. If arrest of further
progression of the mineralization is achieved by these treatment modalities, the implication
is that the treatment should be started as early as possible at the time the diagnosis has
been established. In this context, in case of family history of PXE, potentially susceptible
individuals, particularly unaffected siblings of an affected individual, could be tested by
mutation analysis for presymptomatic diagnosis to include or exclude the possibility of
the disease at a later state, a situation that would allow preventive treatment before the
symptoms develop [85].
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